Staphylokinase variant
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- 凝血基因公司
- Publication Date
- 2013-07-17
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 Figure 2
Abstract
Description
field of invention
[0001] The present invention relates to optimized staphylokinase variants with thrombotic or fibrinolytic activity, low T-cell immunogenicity and low clearance by circulating antibodies expressing high levels. Background technique
[0002] Administration of fibrinolytic agents early in the onset of symptoms of myocardial ischemia can protect myocardial tissue, prevent secondary complications caused by myocardial infarction (congestive heart failure, arrhythmia, etc.), and most importantly - save life. The two most commonly used fibrinolytic agents are streptokinase (SK) and recombinant tissue plasminogen activator (rtPA). Despite the advantage of very low cost, SK is not as effective as rtPA (or mutants of rt-PA) in terms of arterial patency and 30-day mortality (the difference in mortality is maintained for at least two years) with concomitant hypotension , allergic reactions and neutralizing antibodies. Conversely, because rtPA is relatively expensive ...